RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA

随机试验:母体维生素 D 补充剂预防儿童哮喘

基本信息

  • 批准号:
    8433327
  • 负责人:
  • 金额:
    $ 40.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-03-01 至 2014-05-14
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Asthma is one of the leading causes of morbidity in children with 60% of all cases diagnosed by age 3. Thus, finding factors that can lead to prevention of this disease would be of great public health importance. Vitamin D deficiency is highly prevalent among pregnant women, and thus, represents a potentially modifiable factor for the prevention of disease. Due to the effect of vitamin D in modulating immune responses, we believe that vitamin D deficiency in pregnant mothers leads to faulty immune system development in the neonate, predisposing them to asthma and allergy. We have observational data from two independent birth cohort studies that higher maternal intakes of vitamin D during pregnancy are each independently associated with a 50% reduction in risk for recurrent wheezing and asthma in 3- and 5-yr old children. However, in order to recommend this as a universal treatment to prevent asthma, a randomized, controlled, clinical trial is necessary. Therefore, we propose a two arm, double-blind, placebo controlled, randomized, clinical trial of Vitamin D, to determine whether higher vitamin D intake and levels in the pregnant mother will prevent asthma and allergy in the child at age 3. We will identify pregnant women who have asthma or allergies or whose partner has asthma or allergies, from obstetric clinics in the three clinical centers participating in this trial. We will recruit 870 pregnant women during the first trimester of pregnancy and randomize them to one of two treatment arms of a 4-year clinical trial: 4000 IU of Vitamin D in addition to usual prenatal vitamins, n=435; and usual prenatal vitamins alone, n=435. Our primary specific aim is to determine whether adequate vitamin D supplementation in the pregnant mother is associated with reduced incidence of asthma in the child during the first 3 years of life. The sub-aims of the study will include (1) To determine whether adequate vitamin D supplementation in the pregnant mother is associated with reduced secondary outcomes in the child of (a) allergic sensitization, (b) doctor's diagnosis of eczema and (c) lower respiratory tract infections during the first 3 years of life; and (2) To determine whether adequate vitamin D supplementation in the pregnant mother is associated with improved vitamin D status in the mothers and their offspring through measurement of 25(OH)D levels in maternal plasma, cord blood, and children's blood at 1 and 3 yrs of age.
描述(由申请人提供): 哮喘是儿童发病的主要原因之一,其中 60% 的病例是在 3 岁之前诊断出来的。因此,找到能够预防这种疾病的因素对于公共卫生具有重要意义。维生素 D 缺乏症在孕妇中非常普遍,因此,维生素 D 缺乏症是预防疾病的一个潜在可改变因素。由于维生素 D 具有调节免疫反应的作用,我们认为孕妇缺乏维生素 D 会导致新生儿免疫系统发育缺陷,使他们容易患哮喘和过敏。我们从两项独立出生队列研究中获得的观察数据表明,母亲在怀孕期间摄入较高的维生素 D 与 3 岁和 5 岁儿童反复喘息和哮喘的风险降低 50% 独立相关。然而,为了推荐将此作为预防哮喘的普遍治疗方法,需要进行随机、对照的临床试验。因此,我们建议开展一项维生素 D 的双臂、双盲、安慰剂对照、随机临床试验,以确定孕妇较高的维生素 D 摄入量和水平是否会预防 3 岁时孩子的哮喘和过敏。我们将从参与该试验的三个临床中心的产科诊所中识别患有哮喘或过敏的孕妇或其伴侣患有哮喘或过敏的孕妇。我们将招募 870 名怀孕前三个月的孕妇,并将她们随机分配到为期 4 年的临床试验的两个治疗组之一:除了常规的产前维生素外,还服用 4000 IU 维生素 D,n=435;和单独使用常规产前维生素,n=435。我们的主要具体目标是确定怀孕母亲补充足够的维生素 D 是否与降低孩子出生后 3 年内的哮喘发病率有关。该研究的子目标将包括 (1) 确定怀孕母亲补充足够的维生素 D 是否与孩子出生后 3 年内减少以下继发后果相关:(a) 过敏性过敏、(b) 医生诊断为湿疹和 (c) 下呼吸道感染; (2) 通过测量母体血浆、脐带血以及 1 岁和 3 岁儿童血液中的 25(OH)D 水平,确定怀孕母亲补充足够的维生素 D 是否与母亲及其后代维生素 D 状况的改善相关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert Strunk其他文献

Robert Strunk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert Strunk', 18)}}的其他基金

RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    8233351
  • 财政年份:
    2009
  • 资助金额:
    $ 40.9万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    7584414
  • 财政年份:
    2009
  • 资助金额:
    $ 40.9万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    8037103
  • 财政年份:
    2009
  • 资助金额:
    $ 40.9万
  • 项目类别:
RANDOMIZED TRIAL: MATERNAL VITAMIN D SUPPLEMENTATION TO PREVENT CHILDHOOD ASTHMA
随机试验:母体维生素 D 补充剂预防儿童哮喘
  • 批准号:
    7779471
  • 财政年份:
    2009
  • 资助金额:
    $ 40.9万
  • 项目类别:
BEST ADD-ON THERAPY GIVING EFFECTIVE RESPONSES (BADGER)
给出有效反应的最佳附加疗法 (BADGER)
  • 批准号:
    7603411
  • 财政年份:
    2007
  • 资助金额:
    $ 40.9万
  • 项目类别:
Randomized Controlled Trial: VDAART Continuation Study - CCC
随机对照试验:VDAART 继续研究 - CCC
  • 批准号:
    8697357
  • 财政年份:
    2007
  • 资助金额:
    $ 40.9万
  • 项目类别:
Randomized Controlled Trial: VDAART Continuation Study - CCC
随机对照试验:VDAART 继续研究 - CCC
  • 批准号:
    8849478
  • 财政年份:
    2007
  • 资助金额:
    $ 40.9万
  • 项目类别:
TREATING CHILDREN TO PREVENT EXACERBATIONS OF ASTHMA (TREXA)
治疗儿童预防哮喘恶化 (TREXA)
  • 批准号:
    7603413
  • 财政年份:
    2007
  • 资助金额:
    $ 40.9万
  • 项目类别:
CHILDHOOD ASTHMA MANAGEMENT PROGRAM CONTINUATION STUDY/PHASE 2
儿童哮喘管理计划继续研究/第 2 阶段
  • 批准号:
    7603395
  • 财政年份:
    2007
  • 资助金额:
    $ 40.9万
  • 项目类别:
MONTELUKAST OR AZITHROMYCIN FOR REDUCTION OF INHALED CORTICOSTEROIDS IN CHILD
孟鲁司特或阿奇霉素用于减少儿童吸入皮质类固醇
  • 批准号:
    7603404
  • 财政年份:
    2007
  • 资助金额:
    $ 40.9万
  • 项目类别:

相似海外基金

Lung resident Treg suppression of Th2 resident memory T cells in allergic asthma
过敏性哮喘中肺常驻 Treg 对 Th2 常驻记忆 T 细胞的抑制
  • 批准号:
    10664599
  • 财政年份:
    2023
  • 资助金额:
    $ 40.9万
  • 项目类别:
Development of a highly sensitive and specific POCT testing asthma triggering allergic IgE
开发高度敏感和特异的 POCT 测试哮喘触发过敏性 IgE
  • 批准号:
    10600767
  • 财政年份:
    2023
  • 资助金额:
    $ 40.9万
  • 项目类别:
The effects of wildfire exposure on maternal allergic asthma and consequences on neurobiology
野火暴露对母亲过敏性哮喘的影响及其对神经生物学的影响
  • 批准号:
    10727122
  • 财政年份:
    2023
  • 资助金额:
    $ 40.9万
  • 项目类别:
Development of a highly sensitive and specific POCT testing asthma triggering allergic IgE
开发高度敏感和特异的 POCT 测试哮喘触发过敏性 IgE
  • 批准号:
    10817658
  • 财政年份:
    2023
  • 资助金额:
    $ 40.9万
  • 项目类别:
The Role of PON2 in the Development of Non-Allergic Asthma in Obesity
PON2 在肥胖引起的非过敏性哮喘发展中的作用
  • 批准号:
    10533862
  • 财政年份:
    2022
  • 资助金额:
    $ 40.9万
  • 项目类别:
Defining the development of tissue-resident memory Th2 cells in allergic asthma
定义过敏性哮喘中组织驻留记忆 Th2 细胞的发育
  • 批准号:
    10501568
  • 财政年份:
    2022
  • 资助金额:
    $ 40.9万
  • 项目类别:
Lipid shuttling in memory Th2 cell fate and function in allergic asthma
记忆中的脂质穿梭 过敏性哮喘中 Th2 细胞的命运和功能
  • 批准号:
    10572303
  • 财政年份:
    2022
  • 资助金额:
    $ 40.9万
  • 项目类别:
The Role of PON2 in the Development of Non-Allergic Asthma in Obesity
PON2 在肥胖引起的非过敏性哮喘发展中的作用
  • 批准号:
    10734050
  • 财政年份:
    2022
  • 资助金额:
    $ 40.9万
  • 项目类别:
Development of B cell memory in allergic asthma
过敏性哮喘中 B 细胞记忆的发展
  • 批准号:
    10503760
  • 财政年份:
    2022
  • 资助金额:
    $ 40.9万
  • 项目类别:
Break Down Barriers: Respiratory epithelial cells as modulators of dendritic cells during the pathogen associated allergic sensitization and acute asthma exacerbation
打破障碍:在病原体相关的过敏致敏和哮喘急性发作期间,呼吸道上皮细胞作为树突状细胞的调节剂
  • 批准号:
    504226880
  • 财政年份:
    2022
  • 资助金额:
    $ 40.9万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了